RecruitingPhase IIEN originalLung cancerMetastatic / advanced

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonucleic acid (DNA), which is a natural substance in every living organism. DNA acts like a blueprint that tells all the cells in your body how to function. The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2). STEMVAC is given with granulocyte-macrophage colony stimulating factor (GM-CSF) which is being used as an adjuvant to help create a stronger immune response. Giving STEMVAC with GM-CSF to patients while on maintenance therapy for non-small cell lung cancer (NSCLC) may help activate certain immune cells to recognize and kill lung cancer cells.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony diagnoza raka płuca stadium IV
  • Mierzalne ogniska nowotworowe widoczne w badaniach obrazowych
  • Ukończone 3-4 cykle chemioterapii połączonej z immunoterapią bez pogorszenia
  • Otrzymano co najwyżej 2 cykle utrzymującej immunoterapii
  • Co najmniej jedno miejsce w ciele, które można pobrać do badania
  • Ogólny stan zdrowia pozwalający na leczenie (ocena 0-1 w skali ECOG)
  • Oczekiwana długość życia powyżej 6 miesięcy
  • Prawidłowe wyniki badań krwi (liczba białych ciałek, płytek i hemoglobiny)

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 27, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (2)

University of Nebraska Medical Center

Omaha, United States

Fred Hutch/University of Washington Cancer Consortium

Seattle, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.